Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Biotechnology

Healthcare
$31.49 -0.03%

-$0.01 today

Market cap
$3.85B
Beta
0.74
P/E (TTM)
17.3
EPS (TTM)
$1.81
52W Low $19.05High $32.56

Volume 0.00M

Average 2.17M

CPRX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $24.18M rose 35.0% year over year, behind the +42.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 7.3% from the prior quarter. Over 3 fiscal years it compounded at +36.4% a year.

Context

  • Cost of revenue amounted to 14.8% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +35.0% toward the trailing-twelve-month pace of +42.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.18M-7.3% QoQ
Last fiscal yearDec 2025
$87.25M+26.7% YoY
LTMMar 2026
$105.52M+42.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.0%——
1 year+26.7%——
3-year CAGR+36.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
87.25M USD
Year-over-year change
+26.7%
4-year CAGR
+41.3%

Cost of Revenue vs competitors

How CPRX compares with its peers on the latest reported figures

  • CPRX's LTM Mar 2026 cost of revenue of $105.52M is the 3rd highest of the 9 companies compared; the peer median is $61.6M.
  • Its year-over-year change of +42.1% is the 4th highest of 7, against a peer median of +37.2%.
  • Cost of revenue amounts to 17.7% of revenue for CPRX, versus a peer median of 45.5%.
CPRX Competitors Peer median
Cost of Revenue for CPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 2026$382.7M +54.1%+137.7%45.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$244.96M +232.7%+29.8%108.7%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$105.52M +42.1%+36.4%17.7%
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026$80.45M +20.3%+35.8%146.7%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$75.68M +8.6%+7.2%24.6%
SRRKScholar Rock Holding CorporationLTM Sep 2026$47.52M -52.5%+19.2%8336.0%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$11.84M +58.0%+89.1%17.9%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$21K ———
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 —-58.5%0.0%
Peer median (excluding CPRX) $61.6M+37.2%+29.8%45.5%

Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.83M214.2M398.2M491.73M588.99M
Cost of Revenue21.88M34.39M51.97M68.85M87.25M
Gross Profit118.95M179.81M346.24M422.89M501.74M
Gross Margin84.5%83.9%86.9%86.0%85.2%
Research & Development16.94M19.79M93.15M12.65M12.71M
Selling, General & Admin49.63M57.09M133.71M177.74M193.75M
Operating Expenses66.56M77.97M259.43M227.77M243.96M
Depreciation & Amortization192K1.24M32.88M37.77M37.87M
EBITDA52.86M105.96M127.39M254.04M321.39M
EBITDA Margin37.5%49.5%32.0%51.7%54.6%
Operating Income52.39M101.84M86.81M195.12M257.78M
Operating Margin37.2%47.5%21.8%39.7%43.8%
Interest Income00016.06M0
Interest Expense00000
Other Income / Expenses282K2.88M7.7M21.14M25.74M
Income Before Tax52.67M104.72M94.51M216.26M283.52M
Pre-Tax Margin37.4%48.9%23.7%44.0%48.1%
Income Tax Expense13.19M21.64M23.1M52.37M69.19M
Net Income39.48M83.08M71.41M163.89M214.33M
Net Margin28.0%38.8%17.9%33.3%36.4%
EPS (Basic)0.380.800.671.381.75
EPS (Diluted)0.370.750.631.311.68
Weighted Avg Shares103.38M103.37M106.28M118.46M122.29M
Weighted Avg Shares (Diluted)107.8M111.38M113.75M124.94M127.26M

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Intrinsic Alpha fair value

Locked

Current Price

$31.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.